Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM11260C (Efpeglenatide) vs Liraglutide in Type 2 Diabetes
NCT02059564Phase 1Unknown
- Sponsor
- Hanmi Pharmaceutical
- Start
- Dec 2013
- Primary completion
- Oct 2014
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of efpeglenatide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Hanmi Pharmaceutical. Primary endpoint: Pharmacokinetic profile of acetaminophen as a marker for gastric emptying at 13 weeks. Status: unknown.
02
Drugs
efpeglenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02059564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02059564.